Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"National Health Research Institutes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cancer Drug Delivery System Receives US FDA Approval for Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"National Health Research Institutes","sponsor":"Anbogen Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnBogen Therapeutics Receives Approval from U.S. FDA for Phase Ib\/II Protocol Amendment for ABT-101","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by National Health Research Institutes

    Menu

    National Health Research Institutes

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              National Health Research Institutes

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Taiwan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AnBogen Therapeutics Receives Approval from U.S. FDA for Phase Ib/II Protocol Amendment for ABT-101

              Details:

              ABT-101 (DBPR112) demonstrates excellent therapeutic potential and superior safety profile compared to competitors that are under clinical development. It meets challenges of unmet medical needs for cancer drugs targeting exon 20 insertions in HER2.

              Lead Product(s): DBPR112

              Therapeutic Area: Oncology Product Name: ABT-101

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Recipient: Anbogen Therapeutics

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 13, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              National Health Research Institutes

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Taiwan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cancer Drug Delivery System Receives US FDA Approval for Trials

              Details:

              DBPR115 small molecule drug delivery system has a lower production cost and is less likely to cause adverse immune reactions.

              Lead Product(s): DBPR115

              Therapeutic Area: Oncology Product Name: DBPR115

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 18, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY